BioWa, inc. announced today that Martina Molsbergen has joined the Company as Director, Business Development. Ms. Molsbergen will focus her efforts on all aspects of business development, including forming alliances based on BioWa’s ADCC antibody enhancement technologies and maintaining relationships with the Company’s current partnerships.

BioWa, inc. announced today that Martina Molsbergen has joined the Company as Director, Business Development. Ms. Molsbergen will focus her efforts on all aspects of business development, including forming alliances based on BioWa’s ADCC antibody enhancement technologies and maintaining relationships with the Company’s current partnerships.

Ms. Molsbergen was most recently Vice President, Business Development, at Zetiq Technologies Ltd, (Zetiq) an Israeli-based drug discovery company. In this capacity, she initiated, developed and managed numerous partnering relationships involving the discovery and development of novel anticancer therapeutics. Prior to her position with Zetiq, she held the role of Vice President PDS and Business Development with Patheon, Inc., whereby she kick-started a division and lead the company in several growth initiatives.

Ms. Molsbergen earned a B.S. in Chemical Engineering from Drexel University. Ms. Molsbergen will be based in BioWa’s Princeton office.

Dr. Nobuo Hanai, CEO & President of BioWa, commented, “there has been a growing demand from the pharmaceutical and biotechnology industries for antibody-based technologies. In order to satisfy this demand, we are very pleased to have attracted such a highly skilled business development professional. Martina Molsbergen brings forth skill sets necessary to meet the challenges ahead. Her expertise and in-depth knowledge of our industry will be a valuable asset to BioWa as we continue to expand our human antibody technology platform and our product pipeline activities."

About BioWa, Inc.BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co, Ltd, Japan’s largest biotech company. BioWa is the exclusive worldwide licensor of Potelligent Technology. Potelligent Technology creates high antigen-dependent cellular cyto-toxicity (ADCC) monoclonal antibodies. ADCC is a function of the immune system that enhances the ability of antibodies to kill tumor cells. The enhancement of ADCC is seen up to 100 fold in vitro. BioWa is currently developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have Potelligent antibody products in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities.

For more information about BioWa visit its web site at www.biowa.com.